336 related articles for article (PubMed ID: 33126883)
21. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
[TBL] [Abstract][Full Text] [Related]
22. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review.
Al-Showbaki L; Wilson B; Tamimi F; Molto C; Mittal A; Cescon DW; Amir E
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36792122
[TBL] [Abstract][Full Text] [Related]
23. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract][Full Text] [Related]
24. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
25. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
[TBL] [Abstract][Full Text] [Related]
26. The Role of Circulating Tumor DNA in Renal Cell Carcinoma.
Bergerot PG; Hahn AW; Bergerot CD; Jones J; Pal SK
Curr Treat Options Oncol; 2018 Feb; 19(2):10. PubMed ID: 29464405
[TBL] [Abstract][Full Text] [Related]
27. Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy.
Jung SH; Lee CK; Kwon WS; Yun S; Jung M; Kim HS; Chung HC; Chung YJ; Rha SY
Yonsei Med J; 2023 Sep; 64(9):531-540. PubMed ID: 37634629
[TBL] [Abstract][Full Text] [Related]
28. High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2- postmenopausal breast cancer patients treated with everolimus and exemestane.
Kruger DT; Jansen MPHM; Konings IRHM; Dercksen WM; Jager A; Oulad Hadj J; Sleijfer S; Martens JWM; Boven E
Mol Oncol; 2020 Mar; 14(3):490-503. PubMed ID: 31841262
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis.
Gao Y; Zhang K; Xi H; Cai A; Wu X; Cui J; Li J; Qiao Z; Wei B; Chen L
Oncotarget; 2017 Jan; 8(4):6330-6340. PubMed ID: 28009985
[TBL] [Abstract][Full Text] [Related]
30. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
31. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer.
Fan Y; Ying H; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Zheng L
Cancer Biol Med; 2020 Nov; 17(4):1002-1013. PubMed ID: 33299649
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
Jang A; Lanka SM; Jaeger EB; Lieberman A; Huang M; Sartor AO; Mendiratta P; Brown JR; Garcia JA; Farmer T; Sudhaman S; Mahmood T; Pajak N; Calhoun M; Dutta P; ElNaggar A; Liu MC; Barata PC
JCO Precis Oncol; 2023 Jul; 7():e2300131. PubMed ID: 37467457
[TBL] [Abstract][Full Text] [Related]
33. Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
Ebert EBF; McCulloch T; Hansen KH; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 Mar; 141():37-43. PubMed ID: 31945708
[TBL] [Abstract][Full Text] [Related]
34. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N
Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573
[TBL] [Abstract][Full Text] [Related]
35. Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
Koh Y; Nakano K; Katayama K; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Imamura R; Yamaguchi R; Imoto S; Shiotsu Y; Nonomura N; Uemura M
Int J Urol; 2022 May; 29(5):462-469. PubMed ID: 35184335
[TBL] [Abstract][Full Text] [Related]
36. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
37. Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Shatsky R; Parker BA; Bui NQ; Helsten T; Schwab RB; Boles SG; Kurzrock R
Mol Cancer Ther; 2019 May; 18(5):1001-1011. PubMed ID: 30926636
[TBL] [Abstract][Full Text] [Related]
38. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
39. Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer.
Han Y; Wang J; Sun T; Ouyang Q; Li J; Yuan J; Xu B
Signal Transduct Target Ther; 2023 Nov; 8(1):429. PubMed ID: 37973901
[TBL] [Abstract][Full Text] [Related]
40. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]